SUO 2002
Alternative Names: SUO-2002; SUO-2002-SuonoCalmLatest Information Update: 10 Jan 2022
At a glance
- Originator Suono Bio
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ulcerative colitis
Most Recent Events
- 10 Jan 2022 Suono-Bio plans to submit IND application to the US FDA for Ulcerative colitis (Suono-Bio pipeline, January 2022)
- 05 Jan 2022 Preclinical trials in Ulcerative colitis in USA (Intradermal) (Suono-Bio pipeline, January 2022)
- 01 Dec 2021 Suono Bio has patent protection for Formulation-Independent Drug Delivery in USA